Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + SCRT + Chemotherapy in pMMR/MSS LARC
NCT06919510Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in rectal adenocarcinoma (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Adverse events at 6 months, Complete response rate and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06919510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919510.